Azelastine - HCl and fluticasone propionate
CADTH
Record ID 32016000169
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that azelastine hydrochloride/ fluticasone propionate (AZE/FP) not be listed for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0408_Dymista_June-19-2015.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Rhinitis, Allergic, Seasonal
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.